Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature

about

Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature

Item

http://www.wikidata.org/entity/Q35580650

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Effective long-term treatment ...... t and review of the literature

@ast

Effective long-term treatment ...... t and review of the literature

@en

type

Item

label

Effective long-term treatment ...... t and review of the literature

@ast

Effective long-term treatment ...... t and review of the literature

@en

prefLabel

Effective long-term treatment ...... t and review of the literature

@ast

Effective long-term treatment ...... t and review of the literature

@en

P1476

Effective long-term treatment ...... t and review of the literature

@en

P2093

Christian Peschel

http://www.w3.org/2001/XMLSchema#string

Christoph Clemm

http://www.w3.org/2001/XMLSchema#string

Claus Zimmer

http://www.w3.org/2001/XMLSchema#string

Friederike Schmidt-Graf

http://www.w3.org/2001/XMLSchema#string

Katrin Schweneker

http://www.w3.org/2001/XMLSchema#string

Melanie Brügel

http://www.w3.org/2001/XMLSchema#string

Michael Souvatzoglou

http://www.w3.org/2001/XMLSchema#string

Mirjam Hermisson

http://www.w3.org/2001/XMLSchema#string

Philipp J Jost

http://www.w3.org/2001/XMLSchema#string

P2860

IDH1 and IDH2 mutations in gliomas

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

P2888

2162-3619-3-29

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/2162-3619-3-29

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276065492

http://www.w3.org/2001/XMLSchema#string

P6179

1016868244

http://www.w3.org/2001/XMLSchema#string

P698

25954595

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

4423626

http://www.w3.org/2001/XMLSchema#string